Levothyroxine Solvent Composition for Stable Depot Release
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current oral levothyroxine treatments for hypothyroidism face challenges such as inadequate absorption in the GI tract, patient non-compliance, and rapid degradation in aqueous solutions, leading to suboptimal TSH control and health complications.
Innovation Solution
Development of stable, non-aqueous levothyroxine formulations using aprotic polar solvents and ionization stabilizing excipients, which form a depot upon subcutaneous administration, promoting gradual release and improved bioavailability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If oral levothyroxine is administered, then the treatment can be given easily, but the absorption in the GI tract is inadequate and patient compliance is poor
Solution Approach 1:
The patent uses an aprotic polar solvent as an intermediary carrier to deliver levothyroxine directly into the subcutaneous tissue, bypassing the GI tract intermediary that causes absorption problems. This mediator enables reliable drug delivery while maintaining ease of administration through simple injection.
Solution Approach 2:
The patent segments the delivery process by separating the absorption step from the administration step - the drug is administered systemically via injection rather than relying on GI tract absorption, thus eliminating the unreliable absorption intermediary while keeping administration simple.
2Ease of manufacture
If aqueous formulations of levothyroxine are used, then the drug can be dissolved, but the molecule degrades rapidly
Solution Approach 1:
The patent changes the fundamental parameter of the solvent system from aqueous (water-based) to aprotic polar (non-aqueous), which fundamentally alters the chemical environment to prevent degradation while maintaining solubility. This parameter change resolves the contradiction between ease of manufacture and molecular stability.
Solution Approach 2:
The patent employs a composite formulation system combining aprotic polar solvent with specific excipients and ionization stabilizing agents, creating a stable composite material that maintains drug solubility while preventing rapid degradation through the synergistic interaction of its components.
3Productivity
If daily oral regimens are prescribed, then the treatment can be administered, but patient compliance is poor and health complications arise
Solution Approach 1:
The patent implements periodic action by formulating the injection for once-weekly administration, creating a rhythmic treatment schedule that significantly improves patient compliance while maintaining effective thyroid hormone levels throughout the week through the sustained-release depot mechanism.
Solution Approach 2:
The patent applies dynamics by creating a time-release depot system that dynamically releases the drug over time, allowing less frequent administration while maintaining therapeutic efficacy, thus improving compliance without sacrificing treatment productivity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The formulations provide extended therapeutic levels, improved solubility, and stability, enhancing patient compliance and reducing health risks associated with daily oral regimens.
Implementation Method 1
by dissolving a therapeutic agent (active pharmaceutical ingredient), such as levothyroxine, in an aprotic polar solvent system to produce stable therapeutic formulations
Implementation Method 2
the use of aprotic polar solvents, water, and at least one ionization stabilizing agent to prepare stable therapeutic formulations of a variety of active pharmaceutical ingredients
Implementation Method 3
which form a depot upon subcutaneous administration, promoting gradual release and improved bioavailability
Data Source
AI summary
The present invention concerns the use of aprotic polar solvents and an ionization stabilizing agent to prepare stable therapeutic formulations of levothyroxine by dissolving levothyroxine in an aprotic polar solvent system that can then be used to treat, prevent, and/or diagnose certain diseases and disorders in humans and veterinary animals by administration of the formulation thereto. In certain embodiments, the invention is directed to formulations comprising levothyroxine, and optionally one or more additional therapeutic agents, dissolved in an aprotic polar solvent system, such as a DMSO/water admixture comprising at least one ionization stabilizing excipient in a concentration sufficient to impart physical and chemical stability to the therapeutic agent. The invention also provides methods of use of such formulations in treating, preventing, and/or diagnosing diseases and disorders, and methods of manufacturing such formulations.